Meissa Vaccines was founded with a mission to protect people everywhere from deadly respiratory viruses and a commitment to develop innovative technologies capable of delivering effective vaccines at a global scale. Meissa is developing live attenuated vaccine candidates against life threatening respiratory viruses, including respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and human metapneumoviru­­s (hMPV). These vaccine candidates have been developed using the company’s proprietary AttenuBlock   synthetic biology and codon deoptimization platform. Meissa’s vaccine candidates are formulated to be delivered as an intranasal, adjuvant-free, needle-free dose and are designed to prevent infection and disease and generate a strong, durable immune response.